Alto Neuroscience ANRO is a clinical-stage biopharmaceutical company focused on developing medicines for mental health disorders, including depression, bipolar depression and schizophrenia-related cognitive impairment. The company uses a precision psychiatry approach, which involves studying brain-based biomarkers to identify patients who may respond better to specific treatments. This strategy could help address a key limitation of conventional psychiatric medicines. However, the company has no approved commercial products, and its future success depends on clinical study results and regulatory progress.
The company’s pipeline comprises several assets, notably ALTO-207, ALTO-300, ALTO-100 and ALTO-101.
Year to date, shares of Alto have risen 24.1% compared with the industry’s 2.9% growth.
Image Source: Zacks Investment Research
Progress Across ANRO’s Pipeline Programs
ALTO-207 is one of Alto’s key pipeline candidates being developed to treat treatment-resistant depression (TRD), a condition in which patients do not respond adequately to existing therapies. The candidate combines pramipexole, a dopamine agonist approved for Parkinson’s disease that has demonstrated antidepressant effects and ondansetron, a 5-HT3 receptor antagonist used to prevent nausea. The combination is designed to improve tolerability and allow faster dose increases and higher pramipexole dosing.
In mid-2026, the company reported encouraging phase IIa results in major depressive disorder, supporting further development of this treatment approach. The study demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability . Alto is advancing ALTO-207 through its PACE program, which includes three clinical studies for TRD. The ongoing phase IIb PACE-1 study is evaluating ALTO-207 as an add-on, with topline results expected in the second half of 2027. The company plans to start the phase III PACE-2 study of ALTO-207 as an add-on treatment by early 2027. The additional phase III PACE-3 study will evaluate it as a standalone treatment, with initiation expected in the second half of 2027, subject to FDA alignment. Running these studies in parallel could accelerate development and potentially support a broader product label. Alto also expects its patents to protect ALTO-207 through at least the mid-2040s, supporting its long-term commercial potential.
Alto’s other key pipeline candidates, ALTO-300 and ALTO-100, offer additional growth opportunities. ALTO-300 is being developed as an add-on treatment for major depressive disorder, with an electroencephalogram biomarker used to identify patients who may benefit from the therapy. ALTO-100 is being evaluated for bipolar depression in patients selected using a cognitive biomarker. Both candidates are currently in phase IIb studies.
Alto expects to report top-line results for ALTO-300 in the first half of 2027 and for ALTO-100 around mid-2027. Positive clinical data from either program could support further development and expand Alto’s growth prospects in mental health.
Alto is also developing ALTO-101 to address cognitive impairment associated with schizophrenia, which can affect memory, attention and daily functioning. The candidate’s phase II proof-of-concept study failed to meet statistical significance on the primary endpoint in April 2026. However, some secondary and exploratory analyses showed encouraging signals. These findings are not sufficient to establish the treatment’s efficacy. Alto has since developed a modified-release oral formulation and plans to explore potential partnering opportunities for the candidate.
Alto Neuroscience, Inc. Price and Consensus
Alto Neuroscience, Inc. price-consensus-chart | Alto Neuroscience, Inc. Quote
ANRO's Zacks Rank & Estimates
Alto currently carries a Zacks Rank #2 (Buy).
Over the past 60 days, estimates for ANRO’s 2026 loss per share have narrowed from $3.00 to $2.68, while 2027 loss per share estimates have improved from $3.46 to $3.04.
Other Stocks to Consider
Some other better-ranked stocks in the biotech sector are Amarin AMRN and Corcept Therapeutics CORT, each currently sporting a Zacks Rank #1 (Strong Buy) and Aldeyra Therapeutics ALDX, carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.6% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alto Neuroscience, Inc. (ANRO): Free Stock Analysis Report
Amarin Corporation PLC (AMRN): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
Aldeyra Therapeutics, Inc. (ALDX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).